AXIM (AXIM Biotechnologies) Cyclically Adjusted PB Ratio: (As of Jul. 02, 2026)


What is AXIM Biotechnologies Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AXIM Biotechnologies  (OTCPK:AXIM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AXIM Biotechnologies Cyclically Adjusted PB Ratio Related Terms


AXIM Biotechnologies Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Cyclically Adjusted PB Ratio Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AXIM vs ZVSA, HEPA, ISCO: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Cyclically Adjusted PB Ratio falls into.



AXIM Biotechnologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AXIM Biotechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2025 is calculated as:

For example, AXIM Biotechnologies's adjusted Book Value per Share data for the three months ended in Jun. 2025 was:

Adj_Book=Book Value per Share/CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=-0.031/322.5610*322.5610
=-0.031

Current CPI (Jun. 2025) = 322.5610.

AXIM Biotechnologies Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.021 238.638 0.028
201509 -0.019 237.945 -0.026
201512 -0.043 236.525 -0.059
201603 -0.065 238.132 -0.088
201606 -0.067 241.018 -0.090
201609 -0.077 241.428 -0.103
201612 -0.045 241.432 -0.060
201703 -0.055 243.801 -0.073
201706 -0.065 244.955 -0.086
201709 -0.089 246.819 -0.116
201712 -0.115 246.524 -0.150
201803 -0.138 249.554 -0.178
201806 -0.121 251.989 -0.155
201809 -0.106 252.439 -0.135
201812 -0.102 251.233 -0.131
201903 -0.087 254.202 -0.110
201906 -0.100 256.143 -0.126
201909 -0.098 256.759 -0.123
201912 -0.104 256.974 -0.131
202003 -0.003 258.115 -0.004
202006 0.009 257.797 0.011
202009 0.018 260.280 0.022
202012 0.012 260.474 0.015
202103 0.013 264.877 0.016
202106 0.008 271.696 0.009
202109 0.034 274.310 0.040
202112 -0.017 278.802 -0.020
202203 -0.023 287.504 -0.026
202206 -0.023 296.311 -0.025
202209 -0.024 296.808 -0.026
202212 -0.025 296.797 -0.027
202303 -0.028 301.836 -0.030
202306 -0.043 305.109 -0.045
202309 -0.025 307.789 -0.026
202312 -0.031 306.746 -0.033
202403 -0.027 312.332 -0.028
202406 -0.032 314.175 -0.033
202412 -0.033 315.605 -0.034
202503 -0.032 319.799 -0.032
202506 -0.031 322.561 -0.031

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.